The PrEP Access and Coverage Act of 2026 mandates no‑cost coverage for FDA‑approved pre‑exposure and post‑exposure prophylaxis drugs, the administrative fees that accompany them, related laboratory and diagnostic tests, and recommended clinical follow‑up across private employer plans, FEHB, Medicaid, CHIP, Medicare Parts B and D, the VA, TRICARE, and Indian Health Service programs. It also bars preauthorization for those services (with a narrow therapeutically‑equivalent exception), prevents life/disability/long‑term care insurers from penalizing users of PrEP/PEP, and requires HHS to issue implementation guidance and confidentiality protections for family plans.
The bill pairs coverage mandates with implementation tools: a CDC/HHS public and provider education campaign, a grants program to expand PrEP/PEP access for uninsured and underinsured people, monitoring and reporting requirements for plans and agencies, and a private right of action for aggrieved individuals. Key effective dates and cost‑sharing eliminations phase in January 1, 2027; several grant and education provisions run through 2030.
At a Glance
What It Does
Amends PHSA, ERISA, the IRC, Medicare/Medicaid/CHIP, FEHB, VA and DoD law to require coverage without cost‑sharing of FDA‑approved HIV prevention drugs and associated services and prohibits preauthorization for those services except where a therapeutically equivalent drug is covered without preauthorization. It also creates a federal grant program and public/provider education campaigns.
Who It Affects
Private group and individual health plans (including ERISA plans), FEHB carriers, Medicaid and CHIP programs and beneficiaries, Medicare Part B and D beneficiaries, VA and TRICARE users, Indian Health Service patients, insurers offering life/disability/LTC products, state insurance regulators, and safety‑net providers and community organizations eligible for grants.
Why It Matters
This bill removes the common administrative and financial barriers that limit PrEP/PEP uptake—cost‑sharing and prior authorization—while committing federal funding to outreach and provider education. For compliance officers and plan administrators, it creates new coverage mandates, reporting obligations, and exposure to enforcement and litigation; for public health leaders, it promises broadened access with targeted funding.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new mandatory preventive benefit for HIV prevention drugs and all services tied to their safe use. For private and employer plans it inserts a PHSA §2713(a)(5) requirement that plans cover FDA‑approved PrEP/PEP drugs, administrative fees, testing and monitoring, and follow‑up recommended in current US Public Health Service guidelines “without limitation.” It simultaneously bars preauthorization for those services, although plans may require prior authorization only if they already cover a therapeutically equivalent drug without prior authorization.
Federal programs are updated in parallel. FEHB plans must eliminate cost‑sharing for covered HIV prevention drugs and associated care.
Medicaid and CHIP are amended to classify HIV prevention services as a covered mandatory category and to prohibit cost‑sharing for those services; states receive a one‑year implementation cushion if state law changes are needed. Medicare Part B is amended to add HIV prevention services as covered outpatient services and to eliminate coinsurance and the Part B deductible for them; Medicare Part D deductible and cost‑sharing for PrEP drugs are likewise removed for plan years beginning on or after January 1, 2027.The bill removes medication copayments and related diagnostics fees for veterans and requires VA preventive services to list PrEP/PEP explicitly.
TRICARE is changed to require coverage for beneficiaries with no cost‑sharing. The Indian Health Service is authorized to provide unlimited funding for FDA‑approved prevention drugs, related diagnostics, and follow‑up and is explicitly authorized additional appropriations.Beyond coverage mandates, the statute creates implementation and support mechanisms: HHS (with CDC) must run a culturally competent public education campaign and a separate provider education campaign designed to increase prescribing and reduce stigma; a new grant program will fund state, tribal, territory, and directly eligible nonprofit programs to provide PrEP/PEP to uninsured or underinsured people and support outreach, adherence services, and PrEP navigators.
Plans and issuers must submit compliance data annually for ten years; HHS, Labor, and Treasury will monitor compliance, issue guidance and billing/coding tools, assist state regulators, and report to Congress every two years. The bill also strengthens confidentiality for family plans and creates a private right of action allowing individuals or classes to sue for violations and recover attorneys’ fees if they prevail.
The Five Things You Need to Know
The bill prohibits preauthorization for coverage of PrEP/PEP services nationwide, except when a plan imposes prior authorization on a specific FDA‑approved drug but provides a therapeutically equivalent drug without prior authorization.
Effective date for major coverage and cost‑sharing changes is January 1, 2027 — Medicare Part B coinsurance/deductible and Part D deductible/cost‑sharing eliminations take effect for items and plan years on or after that date.
The statute requires group health plans and issuers to submit compliance data to HHS at least annually for ten years and directs HHS, Labor, and Treasury to publish biennial reports identifying noncompliant plans and enforcement steps.
A PrEP/PEP grants program (administered by HHS/CDC) will award funds to states, tribes, territories, and qualifying nonprofits for clinical services, outreach, provider education, and adherence supports; grant authorizations run through fiscal 2030.
The bill creates a private right of action enabling individuals or classes to sue over violations, with prevailing plaintiffs entitled to costs and reasonable attorney’s fees.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Mandatory coverage of FDA‑approved PrEP/PEP and related services
This provision inserts a new paragraph into the preventive services coverage law requiring plans subject to PHSA §2713 to cover any FDA‑approved drug for HIV prevention plus administrative fees, lab diagnostics, and follow‑up recommended in USPHS clinical guidance. Practically, insurers must treat PrEP/PEP like other preventive services covered without cost‑sharing. The statutory text also cross‑references USPSTF guidance on other services—an odd technical insertion—but the central operational change is an unconditional preventive benefit for HIV prevention drugs and their ancillary care.
Ban on prior authorization across PHSA, ERISA and the Tax Code
The bill adds mirror prohibitions across the PHSA, ERISA, and Internal Revenue Code that stop group and individual plans from requiring prior authorization for the covered PrEP/PEP services. The only carve‑out allows a plan to require prior authorization for a particular FDA‑approved drug if the plan already covers a therapeutically equivalent drug without prior authorization — a narrow exception designed to preserve formulary management when equivalent drugs exist while blocking blanket utilization management hurdles.
Federal programs: FEHB, Medicaid and CHIP coverage and no cost‑sharing
FEHB plans must include the new benefit and may not impose cost‑sharing. Medicaid’s eligibility categories are expanded to define HIV prevention services as covered medical assistance, prohibit cost‑sharing for them, and require benchmark plans to include them. CHIP is amended to require child and pregnancy‑related coverage to include those services and to bar cost‑sharing. The statute includes an implementation delay option for states needing legislative changes while fixing January 1, 2027 as the operational date for many provisions.
Medicare eliminates Part B and Part D cost‑sharing for HIV prevention
Medicare Part B is amended to expressly categorize HIV prevention services as covered and to pay 100 percent (eliminating coinsurance) for them, along with an exemption from the Part B deductible. Part D is amended so plan years beginning on or after January 1, 2027 eliminate the deductible and all coinsurance or cost‑sharing for covered drugs used for HIV prevention; corresponding low‑income subsidy rules are adjusted. These are material changes to beneficiary cost exposure and to Medicare program spending mechanics.
Veterans, TRICARE, and Indian Health Service: no copays and explicit program support
VA statutes are adjusted to exempt medications for HIV prevention and associated diagnostics and monitoring from copayments and to list these drugs as preventive health services. DoD/TRICARE must cover the same services with no cost‑sharing for beneficiaries. The IHS receives an explicit new authority (and an open‑ended appropriation authorization) to provide and fund PrEP/PEP drugs, diagnostics and follow‑up without limitation, which supports access on tribal lands and in IHS facilities.
Prohibition on underwriting discrimination by life, disability, and long‑term care insurers
The bill makes it unlawful for life, disability, or long‑term care insurers to deny or limit coverage, set underwriting conditions, or increase premiums based solely on an applicant’s use of medication for HIV prevention. Enforcement responsibility is placed with state insurance regulators under their existing authorities; the provision does not create a new federal enforcement mechanism but preempts discriminatory underwriting on this specific basis.
Public and provider education campaigns and PrEP/PEP grant program
CDC (with HRSA and the Office of Infectious Disease and HIV/AIDS Policy) must run culturally competent public and provider education campaigns focused on high‑need and overrepresented communities, measuring outreach, language services, and workforce cultural competence. Separately, HHS will run a grants program to states, tribes, territories, and qualifying nonprofits to expand clinical access, do outreach, and fund adherence navigators; applicants must identify how funds will reach uninsured and underinsured populations. Both programs include evaluation metrics and are authorized (appropriations) through fiscal 2030.
Confidentiality, private enforcement, and compliance monitoring
HHS must update HIPAA‑related regulations to let individuals access PrEP/PEP benefits under family plans without notifying other family members. The bill creates a federal private right of action enabling individuals or classes to sue for violations and recover attorneys’ fees if they prevail. HHS, Labor, and Treasury are tasked with issuing guidance, developing billing/coding tools, providing technical assistance, collecting annual insurer compliance data for ten years, and issuing biennial reports to Congress identifying noncompliance and enforcement actions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People at elevated risk of HIV (including gay and bisexual men, transgender people, people of color, and sexual partners of people with HIV) — they face greatly reduced financial and administrative barriers to starting and staying on PrEP/PEP.
- Medicare beneficiaries who use PrEP/PEP — Part B and Part D changes eliminate coinsurance and deductible exposure for prevention drugs and related services.
- Veterans, TRICARE beneficiaries, and American Indian/Alaska Native patients served by IHS — those programs will provide PrEP/PEP without copays and with dedicated IHS funding.
- Community health centers, clinics, and nonprofits serving uninsured or underinsured people — eligible for grants to expand services, hire navigators, and support adherence and outreach.
- Patients on family insurance plans who want confidentiality — HHS is required to update regulations so family members need not be notified when a dependent accesses covered HIV prevention services.
Who Bears the Cost
- Private insurers and ERISA plan sponsors — required to cover drugs and associated services without cost‑sharing and to remove prior authorization, which will increase benefit expenditures and administrative reporting obligations.
- Federal programs and taxpayers — Medicare, VA, TRICARE, and IHS will absorb greater direct costs for prevention drugs and diagnostics and the bill authorizes appropriations for grants and campaigns through 2030.
- State insurance regulators and plan administrators — must adjust benefit design rules, enforce the nondiscrimination clause for life/disability/LTC products, and process consumer complaints tied to the new mandates.
- Pharmacy benefit managers and formulary committees — lose a utilization management lever (prior authorization) for most PrEP/PEP drugs, constraining cost control options unless therapeutically equivalent substitutions are available.
- Small community providers receiving grants — must comply with grant reporting, application, and program administration requirements, which can create administrative burdens even as they receive funding.
Key Issues
The Core Tension
The bill forces a tradeoff between rapid, barrier‑free access to proven HIV prevention tools and the fiscal and operational realities of health financing: eliminating cost‑sharing and prior authorization expands uptake but reallocates costs to insurers and federal programs while narrowing traditional utilization management options, leaving unresolved questions about who ultimately bears rising drug and service costs and how to preserve clinical oversight without reintroducing access barriers.
The bill aggressively removes common barriers—prior authorization and cost‑sharing—but does not include a parallel payment‑rate reform or explicit federal budget offsets. That creates an implementation challenge: removing financial barriers will likely increase prescriptions and monitoring visits, shifting substantial costs to insurers and federal programs (Medicare, VA, TRICARE, Medicaid).
Payers will push back through formulary management, negotiated rebates, or network design; the statute leaves room only for a therapeutically‑equivalent exception to prior authorization, not for step therapy or utilization limits, which could drive disputes over clinical equivalence and appropriate formulary placement.
Enforcement and compliance are another tension point. The bill centralizes monitoring with HHS, Labor, and Treasury and requires annual insurer reporting for a decade, but it relies on existing state authority to police life/disability/LTC discrimination and relies heavily on HHS guidance for confidentiality and billing mechanics.
The new private right of action opens the door to litigation as the principal means of enforcement, which can be an effective backstop but also invites costly suits that will test statutory terms like “without limitation” and the scope of covered ancillary services. Finally, the grant and education components are positive for access but are time‑limited (authorizations through 2030) and depend on annual appropriations—so the on‑paper coverage gains could outpace the workforce and outreach capacity needed to deliver care in many high‑need communities.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.